MiMedx Group Plunges 20.74% on CMS Spending Cuts

On July 15, 2025, MiMedx Group's stock experienced a significant drop of 20.74% in pre-market trading.

This dramatic decline was primarily driven by the Centers for Medicare & Medicaid Services (CMS) proposal to slash spending on skin substitutes. The proposed rule aims to significantly reduce costs associated with these medical products, which has had a profound impact on companies like MiMedx Group and Organogenesis Holdings.

Analysts have projected considerable upside potential for MiMedx Group, with price targets suggesting significant growth from current levels. Despite the recent market tremors, the stock maintains an "Outperform" status, indicating positive sentiment from brokerage firms.

The collective judgment from brokerage firms positions MiMedx Group with an average recommendation score of 2.0, signifying an "Outperform" status. This rating system, ranging from 1 to 5, places MiMedx Group closer to the "Strong Buy" end, suggesting strong market confidence.